{"nctId":"NCT00820248","briefTitle":"Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer","startDateStruct":{"date":"2008-12-30","type":"ACTUAL"},"conditions":["Head and Neck Cancer"],"count":320,"armGroups":[{"label":"Arm I","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: cisplatin","Radiation: 3-dimensional conformal radiation therapy","Radiation: intensity-modulated radiation therapy"]},{"label":"Arm II","type":"EXPERIMENTAL","interventionNames":["Biological: panitumumab","Radiation: 3-dimensional conformal radiation therapy","Radiation: accelerated radiation therapy","Radiation: intensity-modulated radiation therapy"]}],"interventions":[{"name":"panitumumab","otherNames":[]},{"name":"cisplatin","otherNames":[]},{"name":"3-dimensional conformal radiation therapy","otherNames":[]},{"name":"accelerated radiation therapy","otherNames":[]},{"name":"intensity-modulated radiation therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically and/or cytologically confirmed (primary lesion or regional lymph nodes) squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx\n\n  * Locally advanced disease, defined by any of the following criteria:\n\n    * Any T, N+, M0\n    * T3-4, N0, M0\n* No current history of unknown primary squamous cell carcinoma of the head and neck, primary nasopharyngeal, paranasal, or salivary gland tumors of the head and neck\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-1\n* Absolute granulocyte count ≥ 1.5 x 10\\^9/L\n* Platelet count ≥ 100 x 10\\^9/L\n* Bilirubin ≤ 1.5 times upper limit of normal (ULN)\n* AST or ALT ≤ 3 times ULN\n* Creatinine clearance \\> 50 mL/min\n* Magnesium \\> 0.5 mmol/L\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment\n* Must be accessible for treatment and follow-up\n* Able (sufficiently fluent) and willing to complete the quality of life (QOL) and swallowing QOL questionnaires in either English or French\n* Must be assessed by a radiation oncologist and medical oncologist and deemed suitable for study participation\n* No other malignancies within the past 5 years, except adequately treated nonmelanoma skin cancer, curatively treated in-situ cancer of the cervix, or other curatively treated solid tumors\n* No history of allergic or hypersensitivity reactions to any of the study drugs or their excipients\n* No prior or concurrent interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) on baseline CT scan\n* No peripheral neuropathy ≥ grade 2 (CTCAE v3.0)\n* No hearing loss/tinnitus ≥ grade 3 (CTCAE v3.0)\n* No thromboembolic event within the past 12 months despite being treated with anticoagulation drugs\n\n  * Prior thromboembolic event \\> 12 months allowed provided patient is stable on anticoagulation or on preventative anticoagulation\n* None of the following allowed:\n\n  * Myocardial infarction within the past 12 months\n  * Uncontrolled severe congestive heart failure\n  * Unstable angina\n  * Active cardiomyopathy\n  * Unstable ventricular arrhythmia\n  * Uncontrolled hypertension\n  * Uncontrolled psychiatric disorder\n  * Active serious infection\n  * Active peptic ulcer disease\n  * Any other medical condition that might interfere with protocol therapy delivery\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior surgical treatment except diagnostic biopsy for this disease\n* No prior induction chemotherapy for this disease\n* No prior radiation to the head and neck region that would result in overlap of fields for this study\n* No prior cisplatin or carboplatin chemotherapy\n* No prior targeted anti-EGFR therapy of any kind\n* At least 30 days since any prior investigational agent\n* No concurrent granulocytic growth factors (e.g., filgrastim \\[G-CSF\\]) during radiotherapy\n* No concurrent erythropoietic growth factors, pilocarpine, amifostine, other anticancer therapy (e.g., cytotoxic agents, biological response modifiers, immunotherapy, or hormonal therapy), or other investigational drug therapy\n* The following radiological investigations must be done within 8 weeks of randomization:\n\n  * MRI or CT of the head and neck\n  * CT chest","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS) Rate","description":"The progression event is defined by first event of the following,\n\nLocal-regional progression or recurrence Distant metastasis Non-protocol RT, chemotherapy, or biologic therapy without documentation of the site of failure Surgery of primary site with tumour present/unknown Neck dissection with tumour present/unknown, \\> 15 weeks from end of RT Death due to study cancer or from unknown causes or any other reason\n\nNumber of patients with and without progression event will be reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"43","spread":null}]},{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"117","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival Rate","description":"Overall survival is defined as the time interval between the date of randomization to date of death from any cause (calculated in months). Otherwise, survival is censored at the last date that the patient is known to be alive.\n\nNumber of death and alive patients will be reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"32","spread":null}]},{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"128","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":156},"commonTop":["Dysphagia","Dry mouth","Taste alteration","Weight loss","Fatigue"]}}}